Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer.
Breast cancer
Mammographic density
Neoadjuvant treatment
Pathological complete response
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Dec 2019
30 Dec 2019
Historique:
received:
27
06
2019
accepted:
20
12
2019
entrez:
1
1
2020
pubmed:
1
1
2020
medline:
6
5
2020
Statut:
epublish
Résumé
Our aim is to study if mammographic density (MD) prior to neoadjuvant chemotherapy is a predictive factor in accomplishing a pathological complete response (pCR) in neoadjuvant-treated breast cancer patients. Data on all neoadjuvant treated breast cancer patients in Southern Sweden (2005-2016) were retrospectively identified, with patient and tumor characteristics retrieved from their medical charts. Diagnostic mammograms were used to evaluate and score MD as categorized by breast composition with the Breast Imaging-Reporting and Data System (BI-RADS) 5th edition. Logistic regression was used in complete cases to assess the odds ratios (OR) for pCR compared to BI-RADS categories (a vs b-d), adjusting for patient and pre-treatment tumor characteristics. A total of 302 patients were included in the study population, of which 57 (18.9%) patients accomplished pCR following neoadjuvant chemotherapy. The number of patients in the BI-RADS category a, b, c, and d were separately 16, 120, 140, and 26, respectively. In comparison to patients with BI-RADS breast composition a, patients with denser breasts had a lower OR of accomplishing pCR: BI-RADS b 0.32 (95%CI 0.07-0.1.5), BI-RADS c 0.30 (95%CI 0.06-1.45), and BI-RADS d 0.06 (95%CI 0.01-0.56). These associations were measured with lower point estimates, but wider confidence interval, in premenopausal patients; OR of accomplishing pCR for BI-RADS d in comparison to BI-RADS a: 0.03 (95%CI 0.00-0.76). The likelihood of accomplishing pCR is indicated to be lower in breast cancer patients with higher MD, which need to be analysed in future studies for improved clinical decision-making regarding neoadjuvant treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Our aim is to study if mammographic density (MD) prior to neoadjuvant chemotherapy is a predictive factor in accomplishing a pathological complete response (pCR) in neoadjuvant-treated breast cancer patients.
METHODS
METHODS
Data on all neoadjuvant treated breast cancer patients in Southern Sweden (2005-2016) were retrospectively identified, with patient and tumor characteristics retrieved from their medical charts. Diagnostic mammograms were used to evaluate and score MD as categorized by breast composition with the Breast Imaging-Reporting and Data System (BI-RADS) 5th edition. Logistic regression was used in complete cases to assess the odds ratios (OR) for pCR compared to BI-RADS categories (a vs b-d), adjusting for patient and pre-treatment tumor characteristics.
RESULTS
RESULTS
A total of 302 patients were included in the study population, of which 57 (18.9%) patients accomplished pCR following neoadjuvant chemotherapy. The number of patients in the BI-RADS category a, b, c, and d were separately 16, 120, 140, and 26, respectively. In comparison to patients with BI-RADS breast composition a, patients with denser breasts had a lower OR of accomplishing pCR: BI-RADS b 0.32 (95%CI 0.07-0.1.5), BI-RADS c 0.30 (95%CI 0.06-1.45), and BI-RADS d 0.06 (95%CI 0.01-0.56). These associations were measured with lower point estimates, but wider confidence interval, in premenopausal patients; OR of accomplishing pCR for BI-RADS d in comparison to BI-RADS a: 0.03 (95%CI 0.00-0.76).
CONCLUSIONS
CONCLUSIONS
The likelihood of accomplishing pCR is indicated to be lower in breast cancer patients with higher MD, which need to be analysed in future studies for improved clinical decision-making regarding neoadjuvant treatment.
Identifiants
pubmed: 31888552
doi: 10.1186/s12885-019-6485-4
pii: 10.1186/s12885-019-6485-4
pmc: PMC6937786
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1272Références
J Pathol Transl Med. 2016 May;50(3):173-80
pubmed: 27068026
Nat Rev Cancer. 2006 Aug;6(8):583-92
pubmed: 16862189
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2090-5
pubmed: 15598766
Br J Cancer. 2004 Dec 13;91(12):2012-7
pubmed: 15558072
Breast Cancer Res. 2014 Sep 20;16(5):439
pubmed: 25239205
Clin Cancer Res. 2004 Oct 1;10(19):6622-8
pubmed: 15475452
Br J Cancer. 2002 Oct 7;87(8):876-82
pubmed: 12373602
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):662-8
pubmed: 15767347
Eur Radiol. 2016 Dec;26(12):4354-4360
pubmed: 27011371
Dis Markers. 2014;2014:513158
pubmed: 24591761
J Natl Cancer Inst. 2011 Aug 3;103(15):1179-89
pubmed: 21795664
Annu Rev Biomed Eng. 2007;9:229-56
pubmed: 17459001
Nat Rev Clin Oncol. 2016 Sep;13(9):566-79
pubmed: 27000962
Cancer Causes Control. 2000 Aug;11(7):653-62
pubmed: 10977110
J Clin Oncol. 2013 Jun 20;31(18):2249-56
pubmed: 23610119
Diagn Interv Imaging. 2017 Mar;98(3):179-190
pubmed: 28131457
Nature. 2013 Sep 19;501(7467):346-54
pubmed: 24048067
Ann Intern Med. 1999 Feb 16;130(4 Pt 1):262-9
pubmed: 10068383
AJR Am J Roentgenol. 2013 Sep;201(3):692-7
pubmed: 23971465
J Clin Oncol. 2006 Mar 1;24(7):1037-44
pubmed: 16505422
PLoS One. 2013 Dec 09;8(12):e81876
pubmed: 24349146
Med Oncol. 2014 Aug;31(8):96
pubmed: 25012685
Cancer Res. 2006 Feb 1;66(3):1866-72
pubmed: 16452249
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):715-22
pubmed: 15159301
Breast Cancer Res. 2013;15(4):R57
pubmed: 23876209
Future Oncol. 2018 Mar;14(7):647-663
pubmed: 29513086
Ann Surg Oncol. 2018 Aug;25(8):2241-2248
pubmed: 29786125
J Natl Cancer Inst. 2010 Aug 18;102(16):1224-37
pubmed: 20616353
Breast. 2015 Oct;24(5):576-81
pubmed: 26071795
Cancer. 2002 Aug 15;95(4):681-95
pubmed: 12209710
Breast. 2015 Feb;24(1):12-7
pubmed: 25433452
Dis Model Mech. 2011 Mar;4(2):165-78
pubmed: 21324931
Acta Radiol Open. 2018 Sep 17;7(9):2058460118791212
pubmed: 30245850
Diagn Interv Imaging. 2012 Feb;93(2):95-103
pubmed: 22305593
Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002
pubmed: 17443564
Medicine (Baltimore). 2017 Dec;96(51):e9384
pubmed: 29390540
Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):102-12
pubmed: 19124487
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
JAMA. 2015 Mar 17;313(11):1122-32
pubmed: 25781441
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
J Clin Pathol. 2017 Nov;70(11):947-953
pubmed: 28465449
N Engl J Med. 2002 Sep 19;347(12):886-94
pubmed: 12239257
J Clin Oncol. 2007 Jul 1;25(19):2650-5
pubmed: 17602071
Br J Cancer. 2003 Feb 10;88(3):406-12
pubmed: 12569384
Breast Cancer Res Treat. 2010 Nov;124(1):133-40
pubmed: 20697801
Breast Cancer Res Treat. 2014 Apr;144(3):479-502
pubmed: 24615497
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):872-9
pubmed: 18398028
Br J Cancer. 2006 Feb 13;94(3):358-62
pubmed: 16421590
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):479-85
pubmed: 19190139